Molecular biomarker‐guided anti‐angiogenic targeted therapy for malignant glioma. Issue 8 (18th June 2019)

• Record Type: Journal Article
• Authors: Yan, Chengrui; Wang, Jiaru; Yang, Yuyan; Ma, Wenbin; Chen, Xiaolin
• Is Part Of: Journal of cellular and molecular medicine. Volume 23:Issue 8(2019)
• Page Start: 4876
• Page End: 4882
• Publication Date: 2019-06-18
• Subjects: anti‐angiogenic -- biomarkers -- glioma -- molecular -- therapy; Cytology; Medicine; Molecular Biology; Cytologie -- Périodiques; Médecine -- Périodiques; Biologie moléculaire -- Périodiques; Cytology -- Periodicals; Medicine -- Periodicals; Molecular biology -- Periodicals; 611.01805
• DOI: 10.1111/jcmm.14417
• Languages: English
• ISSNs: 1582-1838

Abstract

Abstract: Despite aggressive multimodality treatment, the prognosis of glioma, especially malignant glioma, remains very poor. After decades of effort, anti‐angiogenic therapy has become an important method of cancer treatment in addition to surgery, radiotherapy and chemotherapy. Although the performance of anti‐angiogenic therapy in colorectal cancer is good, its performance in malignant glioma remains unsatisfactory. Several phase III clinical trials showed no overall survival benefits. To solve this problem, the division of patients into groups based on their molecular biomarkers is an important step. This paper provides current insights into anti‐angiogenic drugs undergoing clinical trials and discusses the potential of molecular biomarkers to guide glioma diagnosis.